Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Global Payments Executives Are Making a Ton of Trades

Global Payments executives: Earlier this week, J Gerald Wilkins, a Director at Global Payments Inc (NYSE:GPN), reported the purchase of 2,500 company shares at the U.S. Securities and Exchange Commission. The acquisition took place last Friday, at a price of $56.7484 per share, totaling a transaction for $141,871. Following this, Wilkins holds 15,576 shares, valued at $895,152.

A couple of days before this purchase, on Oct. 16th, another insider, I William Jacobs, also a board director, had acquired 6,460 shares, using a non-qualified stock option (right to buy). He paid $19.355 per share and, although he then sold 2,218 on that same day, at the same price; the balance was positive. After the reported transactions, Jacobs owns 44,182 valued at $2,539,139.

Global Payments Inc (NYSE:GPN)

On the other hand, insider selling at Global Payments has been very strong this month. At least three insiders sold substantial amounts of stock (thousands of shares each) this month, reducing their holdings drastically. While one sold about 21% of his shares, the remaining two sold more than half of the stock that they held.

Valued at 17 times its earnings, and at a substantial discount to the 29.5x industry average, this stock does not look so bad. Nevertheless, I should mention that Global Payments is trading at a 52-week high and above its 50-day and 200-day moving averages of $50.68 and $48.49, respectively.

Growth projections are not bad either, and analysts expect the company to deliver average annual EPS growth rates above 10% over the next five years. Moreover, a 0.14% dividend yield sweetens up the deal a little bit.

Disclosure: Javier Hasse holds no position in any stocks mentioned

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!